Rockville MD — October 22 2025
Xcellon Biologics announced that it has received a $990,000 award from the TEDCO Equitech Growth Fund to accelerate the expansion of its antibody drug conjugate (ADC) biomanufacturing facility in Rockville, Maryland. The investment is part of the second round of Equitech Growth Fund awards that support inclusive growth across the Maryland innovation economy.
Read TEDCO’s official announcement.
The TEDCO Equitech Growth Fund advances technology development, workforce inclusion, and regional competitiveness. Through this award, Xcellon will expand cleanrooms, development laboratories, and digital connectivity needed for rapid tech transfer, process development, and GMP readiness in 2026. The facility will operate with single-use, closed systems, designed to shorten time to clinic while maintaining quality and compliance.
“We are honored to receive TEDCO’s support through the Equitech Growth Fund,” said Yuk Chun Chiu, Chief Operating Officer of Xcellon Biologics. “This award strengthens our mission to build scalable, flexible manufacturing that bridges innovation and access, so more patients benefit sooner.”
Moreover, Xcellon’s platform supports the full antibody drug conjugate life cycle, including conjugation strategy selection, linker and payload screening, analytical characterization, and scale-up. In addition, the team focuses on clear critical quality attributes, robust purification, and fit-for-purpose stability programs. These elements collectively ensure a smooth transition into GMP manufacturing.
By partnering early with discovery-stage companies, Xcellon helps align design with manufacturability from day one. Consequently, new ADC programs can progress from concept to clinic with fewer obstacles and faster timelines.
Explore more about Xcellon Biologics:
For inquiries about collaboration or services, please contact the Xcellon team.
